In 2016, the National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) surveyed providers regarding whether angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker (ARB) treatment should be discontinued in patients with chronic kidney disease (CKD) without kidney replacement therapy when estimated glomerular filtration rate (eGFR) decreases to less than 20mL/min/1.73m2. Of note, 53.8% of the 703 respondents answered no, while 46.2% responded yes.1